Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Nephrology
Published in: BMC Nephrology 1/2013

Open Access 01-12-2013 | Research article

Risk of human papillomavirus-related cancers among kidney transplant recipients and patients receiving chronic dialysis - an observational cohort study

Authors: Lars Skov Dalgaard, Ulrik Fassel, Lars Jørgen Østergaard, Bente Jespersen, Ole Schmeltz Søgaard, Søren Jensen-Fangel

Published in: BMC Nephrology | Issue 1/2013

Login to get access

Abstract

Background

Individuals with end-stage renal disease (ESRD) have excess risk of various cancer types. However, the total burden of human papillomavirus-related cancers remains unknown.

Methods

We performed a nationwide observational cohort study during 1994–2010.
For each person with ESRD, we sampled 19 population controls (without ESRD) matched on age, gender and municipality. Participants were followed until first diagnosis of human papillomavirus-related cancer, death, emigration, or 31 December 2010, whichever came first.
Human papillomavirus-related cancers were extracted from Danish medical administrative databases. We considered cancers of the cervix, vulva, vagina, penis, anus, and subsets of head and neck cancers as human papillomavirus-related. We calculated incidence rates of human papillomavirus-related cancer and used Poisson regression to identify risk factors for human papillomavirus-related cancer.

Results

Among 12,293 persons with ESRD and 229,524 population controls we identified 62 and 798 human papillomavirus-related cancers, respectively. Incidence rates of human papillomavirus-related- cancer were 102 per 100,000 person-years (95% confidence interval [CI]; 79.5-131) among persons with ESRD and 40.8 per 100,000 person-years (95% CI; 38.1-43.7) among population controls. ESRD patients had 4.54 (95% CI, 2.48-8.31) fold increased risk of anal cancer and 5.81 fold (95% CI; 3.36-10.1) increased risk of vulvovaginal cancer. Adjusted for age, comorbidity, and sex, ESRD patients had 2.41 (95% CI; 1.83-3.16) fold increased risk of any human papillomavirus-related cancer compared with population controls. Compared with dialysis patients renal transplant recipients had an age-adjusted non-significant 1.53 (95% CI, 0.91-2.58) fold higher risk of human papillomavirus-related cancer.

Conclusions

Persons with ESRD have excess risk of potentially vaccine-preventable human papillomavirus-related cancers.
Appendix
Available only for authorised users
Literature
1.
Kreimer AR, Clifford GM, Boyle P, Franceschi S: Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005, 14 (2): 467-475. 10.1158/1055-9965.EPI-04-0551.CrossRefPubMed
2.
Parkin DM, Bray F: Chapter 2: The burden of HPV-related cancers. Vaccine. 2006, 24 Suppl 3:S3: 11-25.CrossRef
3.
De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S: Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer. 2009, 124 (7): 1626-1636. 10.1002/ijc.24116.CrossRefPubMed
4.
van der Burg SH, Palefsky JM: Human Immunodeficiency Virus and Human Papilloma Virus - why HPV-induced lesions do not spontaneously resolve and why therapeutic vaccination can be successful. J Transl Med. 2009, 7: 108-10.1186/1479-5876-7-108.CrossRefPubMedPubMedCentral
5.
HIV/AIDS NCfIDDo: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recommendations and reports : Morbidity and mortality weekly report Recommendations and reports / Centers for Disease Control. 1992, 41 (RR-17): 1-19.
6.
Vaziri ND, Pahl MV, Crum A, Norris K: Effect of uremia on structure and function of immune system. J Ren Nutr. 2012, 22 (1): 149-156. 10.1053/j.jrn.2011.10.020.CrossRefPubMedPubMedCentral
7.
Sterling KA, Eftekhari P, Girndt M, Kimmel PL, Raj DS: The immunoregulatory function of vitamin D: implications in chronic kidney disease. Nat Rev Nephrol. 2012, 8 (7): 403-412. 10.1038/nrneph.2012.93.CrossRefPubMed
8.
Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, Yuzawa Y, Tranaeus A, Stenvinkel P, Lindholm B: Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol. 2008, 3 (5): 1526-1533. 10.2215/CJN.00950208.CrossRefPubMedPubMedCentral
9.
Engels EA, Pfeiffer RM, Fraumeni JF, Kasiske BL, Israni AK, Snyder JJ, Wolfe RA, Goodrich NP, Bayakly AR, Clarke CA, et al: Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011, 306 (17): 1891-1901. 10.1001/jama.2011.1592.CrossRefPubMedPubMedCentral
10.
Vajdic CM, McDonald SP, McCredie MRE, van Leeuwen MT, Stewart JH, Law M, Chapman JR, Webster AC, Kaldor JM, Grulich AE: Cancer incidence before and after kidney transplantation. JAMA. 2006, 296 (23): 2823-2831. 10.1001/jama.296.23.2823.CrossRefPubMed
11.
Villeneuve PJ, Schaubel DE, Fenton SS, Shepherd FA, Jiang Y, Mao Y: Cancer incidence among Canadian kidney transplant recipients. Am J Transplant. 2007, 7 (4): 941-948. 10.1111/j.1600-6143.2007.01736.x.CrossRefPubMed
12.
Adami J, Gabel H, Lindelof B, Ekstrom K, Rydh B, Glimelius B, Ekbom A, Adami HO, Granath F: Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer. 2003, 89 (7): 1221-1227. 10.1038/sj.bjc.6601219.CrossRefPubMedPubMedCentral
13.
Birkeland SA, Storm HH, Lamm LU, Barlow L, Blohme I, Forsberg B, Eklund B, Fjeldborg O, Friedberg M, Frodin L, et al: Cancer risk after renal transplantation in the Nordic countries, 1964–1986. Int J Cancer. 1995, 60 (2): 183-189. 10.1002/ijc.2910600209.CrossRefPubMed
14.
Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, Wolfe RA, Jones E, Disney AP, Briggs D, et al: Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet. 1999, 354 (9173): 93-99. 10.1016/S0140-6736(99)06154-1.CrossRefPubMed
15.
Shebl FM, Warren JL, Eggers PW, Engels EA: Cancer risk among elderly persons with end-stage renal disease: a population-based case–control study. BMC Nephrol. 2012, 13: 65-10.1186/1471-2369-13-65.CrossRefPubMedPubMedCentral
16.
Group FIS: Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007, 356 (19): 1915-1927.CrossRef
17.
Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, et al: Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009, 374 (9686): 301-314. 10.1016/S0140-6736(09)61248-4.CrossRefPubMed
18.
Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, et al: Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007, 356 (19): 1928-1943. 10.1056/NEJMoa061760.CrossRefPubMed
19.
Kreimer AR, Gonzalez P, Katki HA, Porras C, Schiffman M, Rodriguez AC, Solomon D, Jimenez S, Schiller JT, Lowy DR, et al: Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol. 2011, 12 (9): 862-870. 10.1016/S1470-2045(11)70213-3.CrossRefPubMedPubMedCentral
20.
Palefsky JM, Giuliano AR, Goldstone S, Moreira ED, Aranda C, Jessen H, Hillman R, Ferris D, Coutlee F, Stoler MH, et al: HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011, 365 (17): 1576-1585. 10.1056/NEJMoa1010971.CrossRefPubMed
21.
Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, der Meer DM B-v, Vloon AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW, et al: Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009, 361 (19): 1838-1847. 10.1056/NEJMoa0810097.CrossRefPubMed
22.
Birkeland SA, Lokkegaard H, Storm HH: Cancer risk in patients on dialysis and after renal transplantation. Lancet. 2000, 355 (9218): 1886-1887. 10.1016/S0140-6736(00)02298-4.CrossRefPubMed
23.
24.
Hommel K, Rasmussen S, Madsen M, Kamper AL: The Danish registry on regular dialysis and transplantation: completeness and validity of incident patient registration. Nephrol Dial Transplant. 2010, 25 (3): 947-951. 10.1093/ndt/gfp571.CrossRefPubMed
25.
Pedersen CB, Gotzsche H, Moller JO, Mortensen PB: The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull. 2006, 53 (4): 441-449.PubMed
26.
Ryerson AB, Peters ES, Coughlin SS, Chen VW, Gillison ML, Reichman ME, Wu X, Chaturvedi AK, Kawaoka K: Burden of potentially human papillomavirus-associated cancers of the oropharynx and oral cavity in the US, 1998–2003. Cancer. 2008, 113 (10 Suppl): 2901-2909.CrossRefPubMed
27.
Lynge E, Sandegaard JL, Rebolj M: The Danish national patient register. Scand J Public Health. 2011, 39 (7 Suppl): 30-33. 10.1177/1403494811401482.CrossRefPubMed
28.
Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH: The Danish national hospital register. A valuable source of data for modern health sciences. Dan Med Bull. 1999, 46 (3): 263-268.PubMed
29.
Gjerstorff ML: The Danish cancer registry. Scand J Public Health. 2011, 39 (7 Suppl): 42-45. 10.1177/1403494810393562.CrossRefPubMed
30.
Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987, 40 (5): 373-383. 10.1016/0021-9681(87)90171-8.CrossRefPubMed
31.
Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sorensen HT: The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol. 2011, 11: 83-10.1186/1471-2288-11-83.CrossRefPubMedPubMedCentral
32.
Jensen AR, Overgaard J, Storm HH: Validity of breast cancer in the Danish Cancer Registry. A study based on clinical records from one county in Denmark. Eur J Cancer Prev. 2002, 11 (4): 359-364. 10.1097/00008469-200208000-00007.CrossRefPubMed
33.
Gammelager H, Christiansen CF, Johansen MB, Borre M, Schoonen M, Sorensen HT: Quality of urological cancer diagnoses in the Danish National Registry of Patients. Eur J Cancer Prev. 2012, 21 (6): 545-551. 10.1097/CEJ.0b013e328351c680.CrossRefPubMed
34.
Helqvist L, Erichsen R, Gammelager H, Johansen MB, Sorensen HT: Quality of ICD-10 colorectal cancer diagnosis codes in the Danish National Registry of Patients. Eur J Cancer Care (Engl). 2012, 21 (6): 722-727. 10.1111/j.1365-2354.2012.01350.x.CrossRef
35.
Norgaard M, Skriver MV, Gregersen H, Pedersen G, Schonheyder HC, Sorensen HT: The data quality of haematological malignancy ICD-10 diagnoses in a population-based hospital discharge registry. Eur J Cancer Prev. 2005, 14 (3): 201-206. 10.1097/00008469-200506000-00002.CrossRefPubMed
36.
Bigaard J, Hariri J, Lynge E: Cervical cancer screening in Denmark. Eur J Cancer. 2000, 36 (17): 2198-2204. 10.1016/S0959-8049(00)00309-9.CrossRefPubMed
37.
Lynge E, Arffmann E, Erbs K, Hansen KC, Henriksen B, Holten IW, Holund B, Jakobsen AB, Jespersen NB, Olesen F, et al: [Status of preventive screening for uterine cervix cancer in Denmark in 1994]. Ugeskr Laeger. 1994, 156 (4): 471-473.PubMed
38.
Rayner HC, Pisoni RL, Bommer J, Canaud B, Hecking E, Locatelli F, Piera L, Bragg-Gresham JL, Feldman HI, Goodkin DA, et al: Mortality and hospitalization in haemodialysis patients in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2004, 19 (1): 108-120. 10.1093/ndt/gfg483.CrossRefPubMed
39.
van Leeuwen MT, Webster AC, McCredie MR, Stewart JH, McDonald SP, Amin J, Kaldor JM, Chapman JR, Vajdic CM, Grulich AE: Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study. BMJ. 2010, 340: c570-10.1136/bmj.c570.CrossRefPubMedPubMedCentral
40.
D’Andrilli G, Bovicelli A, Giordano A: HPV vaccines: state of the art. J Cell Physiol. 2010, 224 (3): 601-604. 10.1002/jcp.22174.CrossRefPubMed
41.
42.
Future II study Group: Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis. 2007, 196 (10): 1438-1446.CrossRef
43.
Olsson SE, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, et al: Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin. 2009, 5 (10): 696-704. 10.4161/hv.5.10.9515.CrossRefPubMed
44.
Keam SJ, Harper DM: Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix]. Drugs. 2008, 68 (3): 359-372. 10.2165/00003495-200868030-00007.CrossRefPubMed
45.
McCormack PL, Joura EA: Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil(R)): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women. Drugs. 2010, 70 (18): 2449-2474. 10.2165/11204920-000000000-00000.CrossRefPubMed
Metadata
Title
Risk of human papillomavirus-related cancers among kidney transplant recipients and patients receiving chronic dialysis - an observational cohort study
Authors
Lars Skov Dalgaard
Ulrik Fassel
Lars Jørgen Østergaard
Bente Jespersen
Ole Schmeltz Søgaard
Søren Jensen-Fangel
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2013
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/1471-2369-14-137

Other articles of this Issue 1/2013

BMC Nephrology 1/2013 Go to the issue

Research article

Acetate free citrate-containing dialysate increase intact-PTH and BAP levels in the patients with low intact-PTH

Research article

Prognostic utility of plasma S100A12 levels to establish a novel scoring system for predicting mortality in maintenance hemodialysis patients: a two-year prospective observational study in Japan

Case report

Autosomal dominant polycystic kidney disease in a family with mosaicism and hypomorphic allele

Research article

Proton pump inhibitors and acute kidney injury: a nested case–control study

Research article

Clinical utility of gray scale renal ultrasound in acute kidney injury

Study protocol

Cardiovascular risk and mortality in end-stage renal disease patients undergoing dialysis: sleep study, pulmonary function, respiratory mechanics, upper airway collapsibility, autonomic nervous activity, depression, anxiety, stress and quality of life: a prospective, double blind, randomized controlled clinical trial
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits